Press Release

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders

LOS ANGELES, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (“DOD”) Congressionally Directed Medical Research Programs (“CDMRP”) to evaluate its lead development candidate in ALS. The DOD grant will be used to study the effects of Spinogenix’s lead compound in human iPSCs (induced pluripotent stem cells) from patients with ALS and from healthy volunteers. Additional experiments will be conducted in animal models of ALS.

Spinogenix’s lead drug candidate has a unique mechanism of action wherein it induces an increase in synapses, the key connections between neurons that allow us to think, plan, remember and control motor functions, faculties that are diminished in neurodegenerative diseases including ALS. “We are pleased that the DoD has recognized the potential of our novel drug candidate to change the course of disease progression in ALS,” stated Stella Sarraf, Ph.D., Founding Chief Executive Officer at Spinogenix.

There is an unmet need for new innovative therapeutics for ALS (Lou Gehrig’s disease) which is almost invariably fatal within 3-5 years of diagnosis. The therapies that are currently approved for ALS provide very modest extension of life of several months and are not well tolerated by all patients.

Dr. Merit Cudkowicz, Director of the Sean M. Healey and AMG Center for ALS at Mass General Hospital, commented, “Spinogenix’s novel approach has the potential to demonstrate that replacing lost synapses may result in drugs that can provide a meaningful benefit for patients with ALS.”

About Spinogenix 
Spinogenix was founded with the mission to develop transformative therapeutics for diseases involving synaptic loss and dysfunction. Our drugs are designed to regenerate synapses to reverse declines in cognitive and motor function and fundamentally change treatment paradigms by restoring neuronal connections regardless of the underlying cause of synapse loss. Synapse loss is associated with a variety of neurological and psychiatric diseases, such as ALS, Alzheimer’s disease, Parkinson’s disease, and schizophrenia. More information on Spinogenix can be found at www.spinogenix.com. 

Disclosure
This project is supported by the National Institute on Aging of the National Institutes of Health under award number R44AG082648. The content is solely the responsibility of the Company and Principal Investigators and does not necessarily represent the official views of the National Institutes of Health.

For more information contact info@spinogenix.com.

Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia

Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome

Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease

Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome

Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)